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Abstract
BACKGROUND—The incidence of endometrial cancer increases with age and is associated with 
medical comorbidities such as obesity and diabetes. While a few cohort studies of less than 500 
patients showed an association between comorbidity and survival in endometrial cancer patients, 
the degree of association needs to be better described. The Adult Comorbidity Evaluation 27 
(ACE-27) is a validated comorbidity instrument that provides a score (0–3) based on the number 
and severity of medical comorbidities.
OBJECTIVE—This study was performed to explore the association between medical 
comorbidities and survival of endometrial cancer patients.
STUDY DESIGN—Patients diagnosed with endometrial cancer from 2000–2012 were identified 
from the prospectively maintained Siteman Cancer Center tumor registry. Patients undergoing 
primary surgical treatment for endometrioid, serous and clear cell endometrial carcinoma were 
included. Patients primarily treated with radiation, chemotherapy or hormone therapy were 
excluded. Patients with uterine sarcomas or neuroendocrine tumors were excluded. Patients with 
missing ACE-27 scores were also excluded from analysis. Information including patient 
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demographics, ACE-27 score, tumor characteristics, adjuvant treatment and survival data were 
extracted from the database. The association of ACE-27 and overall as well as recurrence-free 
survival was explored in a multivariable Cox regression analysis after controlling for variables 
found to be significantly associated with survival in univariable analysis.
RESULTS—A total of 2073 patients with a median age of 61 years (range 20–94) at diagnosis 
were identified. ACE-27 score was 0, 1, 2 and 3 in 22%, 38%, 28% and 12% of patients, 
respectively. Stage distribution was I (73%), II (5%), III (15%) and IV (7%) and grade distribution 
was 1 (52%), 2 (23%) and 3 (25%). Most patients had endometrioid histology (87%) followed by 
serous (11%) and clear cell (3%). The median OS for the entire cohort was 54 months [95% 
confidence interval (CI) 3, 154 months] and median PFS was 50 months [95% CI 2, 154 months].
On univariable analysis, age, race, marital status, stage, grade, histology and treatment type were 
significantly associated with overall survival and recurrence-free survival. After adjusting for these 
covariates, patients with ACE-27 score of 2 had a 52% higher risk of death [95% CI 1.16, 2.00] 
and patients with ACE-27 score of 3 had a 2.35-fold increased risk of death [95% CI 1.73, 3.21] 
compared to patients with an ACE-27 score of 0. Similarly, patients with ACE-27 score of 2 had a 
38% higher risk of recurrence [95% CI 1.07, 1.78] and patients with ACE-27 score of 3 had a 
2.05-fold increased risk of recurrence [95% CI 1.53, 2.75] compared to patients with an ACE-27 
score of 0. We found no interaction between ACE-27 score and age, stage or treatment type.
CONCLUSIONS—Our findings demonstrate the importance of comorbidities in estimating the 
prognosis of endometrial cancer patients, even after adjusting for age and known tumor-specific 
prognostic factors like stage, grade, histology and adjuvant treatment.
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INTRODUCTION
The probability of developing endometrial cancer (EC) increases with age and its incidence 
has increased in all age groups over the last decade.1 Advancing age is also associated with a 
higher risk of recurrence and poor survival.2, 3 As a result, age is used in risk-stratification 
algorithms of early stage EC trials. 4, 5 Endometrial cancer is also associated with comorbid 
conditions including obesity and diabetes6 and more than 50% of patients with early stage 
EC die from intercurrent illnesses rather than cancer.4 Therefore, it is important to study the 
effect of comorbidities on the survival of these patients.
Medical comorbidities can strongly affect cancer patient survival and life-expectancy, 
independent of cancer stage and disease status.7, 8 Comorbidity is an independent prognostic 
factor affecting survival in other gynecologic cancers including cervical and ovarian 
cancer.9–11 Nicholas and colleagues showed that a diagnosis of diabetes and/or hypertension 
in EC patients resulted in a decreased survival even after adjusting for age, stage and 
grade.12 Truong and colleagues studied the effect of age, Karnofsky performance status and 
Charlson comorbidity score on the treatment, recurrence and survival of EC patients.13 They 
found that advanced age was associated with a decline in prescribed postoperative radiation 
therapy. Age and performance status were independent predictors of overall survival (OS) 
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but not recurrence-free survival (RFS). A Charlson comorbidity scores of 0–1 versus ≥2 was 
not significantly associated with adjuvant treatment prescribed, OS or RFS. However, there 
was a trend towards prescribing less radiation therapy in patients with score ≥2 when 
compared to patients with score 0–1.
The Charlson comorbidity index was developed to predict the probability of mortality in 
patients with medical comorbidities.14 A score of ≥3 is associated with an almost 60% 1-
year mortality rate. The score is based on age and 16 medical conditions, but the severity of 
the condition is only accounted for in diabetes, cancer and liver disease. Furthermore, it does 
not take into account morbidity from obesity, which is a well-established risk factor for EC. 
In comparison, the Adult Comorbidity Evaluation 27 (ACE-27) is a 26-item comorbidity 
index accounting for the presence and severity of individual medical illnesses by grading 
them into 1 of 4 comorbidity classes – none, mild, moderate or severe (Table 1).15 Comorbid 
conditions that are controlled with or without medications, do not cause symptoms limiting 
activities of daily living (ADLs) and have not required hospitalization are considered mild. If 
patients require active treatment modifications, have residual disability limiting ADLs or 
required hospitalization or surgery to treat comorbid conditions, they are classified as 
moderate. Comorbid conditions that have caused major complications, irreversible end-
organ damage, uncontrolled symptoms and disability requiring full support in ADLs are 
considered severe. A body mass index less than 38 received a score of 1 and all others 
received a score of 2. The overall ACE-27 score can be none (0), mild (1), moderate (2) or 
severe (3) and is defined according to the highest scored ailment. In cases with two or more 
grade 1 ailments, a final score of 1 assigned. In cases with two or more grade 2 ailments in 
different organ systems, a final score of 3 is assigned. ACE-27 has been validated to provide 
prognostic information about cancer patients in large prospectively maintained tumor 
registries.16–18
Read et al reviewed the prognostic impact of ACE-27 score in different cancer types and 
found that comorbidity had the most prognostic impact in patients with a high cancer 
survival rates.19 In the US, the 5-year survival rate from endometrial cancer is >80%.1 
Therefore, it is important to describe the relationship between comorbidity and survival in 
these patients. The objective of this study was to assess the association between ACE-27 
score and survival outcomes including OS and recurrence-free survival (RFS) in patients 
with endometrial cancer.
METHODS
Study design and setting
We performed a retrospective cohort study of women diagnosed with endometrial cancer 
from 2000 to 2012. After Institutional Review Board approval, patients were identified from 
the prospectively maintained Siteman cancer center tumor registry. The analysis included 
surgically treated patients with stages I-IV disease. Only patients with endometrioid, serous 
and clear cell adenocarcinoma were included in the analysis. Thus, we excluded patients 
with uterine sarcomas. Patients primarily treated with hormones, radiation or chemotherapy 
were excluded. Patients with missing ACE-27 data were excluded.
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Data collection
We extracted demographic data from the database including age of diagnosis, race and 
marital status. Medical information regarding alcohol use, tobacco use, ACE-27 score, 
surgical procedure, cancer stage, grade, histology, and adjuvant treatment was also collected. 
Age was divided into the 3 risk categories described by Keys et al.4 ACE-27 scores were 
entered into the database by trained certified tumor registrars after a comprehensive review 
of patient medical records. Tumor stage was based on the 2009 International Federation of 
Gynecology and Obstetrics (FIGO) guidelines. Histology was coded as serous or clear cell if 
more than 10% of the tumor consisted of that histology. The dates of death and recurrence 
were extracted from the database. Death and recurrence information is updated in the 
database semiannually by contacting patients, their family, and their physicians. The 
National and Social Security Death Index is queried for the patients lost to follow-up.
The primary outcome was overall survival (OS) and secondary outcome was recurrence-free 
survival (RFS). OS was calculated from date of diagnosis to date of death or last follow-up. 
Patients who were alive at last follow-up were censored for OS analysis. RFS was calculated 
from date of diagnosis to date of recurrence (after remission) or progression (despite primary 
treatment) or death. Recurrence and progression was determined by computed tomography 
imaging or biopsy.
Statistical analysis
Standard descriptive statistics were used to describe the study cohort. Median, range and 
95% confidence interval (CI) were used to describe continuous variables like age of 
diagnosis, follow-up time, OS and RFS. Categorical variables were described as proportions 
of the entire cohort. Kaplan-Meier survival analysis with log-rank test was used to determine 
the statistical significance of difference in survival between patients with increasing ACE-27 
score. Univariable Cox proportional hazards regression was used to identify factors 
associated with OS and PFS. Variables identified as significantly associated with OS at alpha 
level 0.05 were included in the multivariable model. If a covariate did not meet statistical 
significance on univariate analysis but was deemed clinically important, it was included in 
the multivariable model. Alcohol use was excluded in the multivariable model as ACE-27 
includes this data point. Unadjusted and adjusted hazard ratios (HRunadj and HRadj) for death 
and recurrence were calculated with 95% CI. The proportional hazards assumptions was 
tested by log minus log plots.
RESULTS
Description of cohort
We identified 2519 patients with endometrial cancer from the Siteman Cancer Center tumor 
registry. We excluded 175 patients who did not undergo surgery, 206 patients with ineligible 
histology and 65 patients with missing ACE-27 scores (Figure 1). The distribution of 
variables was not different in the 65 patients with missing ACE-27 score. Most patients had 
a mild comorbidity score followed by moderate, none, then severe. The distribution of 
variables is presented in Table 2. Most patients were white, married or in a partnership and 
had never used alcohol or tobacco. Most patients had stage I and grade 1 cancers with 
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endometrioid histology. The median age of the entire cohort and the patients with recurrence 
was 61 (range 20–94) and 65 (range 34–92) years, respectively. Of the 2073 evaluable 
patients, 310 (15%) recurred, 515 (25%) died and 242 (12%) recurred and died. The 
majority of patients were alive without disease (72%) with a median follow-up time of 63 
months [95% CI 5, 158]. The median OS and PFS was 54 [95% CI 3, 155] and 51 months 
[95% CI 2, 155], respectively.
Kaplan-Meier survival by ACE-27 score
Kaplan-Meier survival plots of OS and PFS for the 4 different ACE-27 scores are shown in 
Figure 2. The overall log-rank test shows there is a significant difference in OS (p<0.001) 
and PFS (Chi-square 16.9, p=0.001) between the different ACE-27 scores. Pairwise 
comparisons between the difference ACE-27 scores show that the OS and PFS for patients 
with a severe ACE-27 score is worse than a score of none, mild or moderate. The 
proportions of death was 100/456 (21.9%), 214/798 (26.8), 124/576 (21.5) and 77/243 
(31.7%) for none, mild, moderate and severe score, respectively. The median time to death 
was 12.7 years for patients with moderate comorbidity and 10.4 years [95% CI 7.2, 13.5] for 
patients with severe comorbidity. Median survival was not reached for patients with none or 
mild comorbidity. After stratifying by stage, a higher grade of comorbidity was still 
associated worse survival for stages 1, 3 and 4 (Figure 3).
Univariable and multivariable Cox regression
The association between patient and tumor characteristics and survival outcomes is shown in 
Table 2. On univariable analysis, both OS and PFS were worse with increasing age, black 
race, widowed or single marital status, increasing ACE-27 score, higher tumor stage, higher 
grade and serous or clear cell histology. PFS was also associated with the same covariates.
After adjusting for age, race, marital status, tobacco use, tumor stage, grade, histology and 
adjuvant treatment, higher ACE-27 score was still associated with worse survival (Table 3). 
Patients with moderate comorbidity had a 52% higher risk of death [HRadj 95% CI 1.16, 
2.00] and patients with severe comorbidity had a 2.35-fold increased risk of death [HRadj 
2.35, 95% CI 1.73, 3.21] compared to patients with a comorbidity category of none. Also, 
patients with moderate comorbidity had a 38% higher risk of recurrence [HRadj 95% CI 
1.07, 1.78] and patients with severe comorbidity had 2.05-fold increased risk of recurrence 
[HRadj 95% CI 1.53, 2.75] compared to patients with comorbidity score of none. Age, 
marital status, tobacco use, tumor stage, grade and serous histology remained independent 
predictors of survival and recurrence.
We also used Cox regression modeling to evaluate for interactions between variables. There 
was no interaction between ACE-27 score and age, stage or adjuvant treatment type. There 
was also no interaction between age and stage or adjuvant treatment type. There was an 
anticipated significant interaction between stage and treatment type. As expected, most stage 
I patients (83%) did not receive adjuvant therapy. Stage II patients were more likely to 
receive radiation (46%), most stage III patients (41%) received a combination of 
chemotherapy and radiation, and most stage IV patients (73%) received chemotherapy alone 
(p<0.001) (Table 4). Adjuvant treatment with chemotherapy was associated with a 35% 
BINDER et al. Page 5
Am J Obstet Gynecol. Author manuscript; available in PMC 2017 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
reduction in risk of death [HRadj 0.65, 95% CI 0.47, 0.90] and combination chemo-radiation 
was associated with a 51% reduction in risk of death [HRadj 0.49, 95% CI 0.35, 0.70] 
compared to patients not receiving adjuvant therapy for all patients when adjusted for all 
covariates included in multivariable analysis (Table 3).
COMMENTS
In our cohort of over 2000 endometrial cancer patients, increasing ACE-27 score was 
associated with decreased overall and recurrence-free survival. Moreover, this association 
was still seen after adjusting for known prognostic factors like age, race, tobacco use, cancer 
stage, grade, histology and adjuvant therapy. Specifically, the risk of death in patients with a 
severe comorbidity score is double the risk in patients without comorbidities. The 
association was also apparent in both early and late stages of cancer, although the magnitude 
of association was higher in early-stage disease. This is consistent with previous studies 
which show that comorbidity is particularly important in patients with indolent cancers and 
longer mean survival.16, 19 Therefore, accurate assessment and documentation of 
comorbidities is of utmost importance in early-stage EC patients.
Nicholas and colleagues showed that diabetes and hypertension were associated with 
decreased survival, whereas obesity, estrogen exposure and smoking were not associated 
with survival in EC patients.12 While obesity may put patients at higher risk of surgical 
morbidity, Temkin et al and Modesitt et al showed that it was not an independent predictor 
of progression or overall survival but likely related to other comorbid conditions.20,21 Given 
the possibility of multi-collinearity between individual comorbid conditions and survival, the 
use of a standardized comorbidity index while studying survival in EC patients is more 
appropriate. Truong and colleagues showed that age and performance status were 
independent predictors of survival but the Charlson comorbidity index was not.13 They also 
showed that advanced age was associated with less aggressive adjuvant therapy and 
Charlson comorbidity score of ≥2 had a trend towards less aggressive radiation therapy. We 
studied a much larger cohort with more than 4 times the patients as previous studies. Unlike 
previous studies, the ACE-27 index evaluated in this study was significantly associated with 
overall survival and there was no significant interaction between age or ACE-27 score and 
administration of postoperative adjuvant treatment.
The ACE-27 tool was developed by Drs. Piccirillo and Littenberg after modification from 
the Kaplan-Feinsten index. Individual comorbid conditions assessed in this instrument 
include a combination of previously researched comorbidities and other important 
conditions not included in the Kaplan-Feinstein or Charlson comorbidity index.15 It is the 
preferred comorbidity tool for our purposes as it was developed for cancer patients, it takes 
into account the presence and severity of multiple medical ailments that can affect cancer 
treatment, it includes obesity as an ailment which is a well-known risk factor for endometrial 
cancer and it is determined after a thorough medical record chart review rather than billing 
codes. The prognostic use of this instrument has been validated in a hospital-based cancer 
registry that included 2535 patients with gynecologic cancers.16 We showed that ACE-27 
score was a predictor of OS and PFS in EC after adjusting for age and well-established 
cancer-related prognostic factors like stage, grade, histology and adjuvant treatment. Age 
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has already been incorporated into risk-stratification algorithms for early-stage endometrial 
cancer. Adding ACE-27 scores to prognostic prediction models may allow more accurate 
assessments of survival as well as benefit from adjuvant therapy.
The strengths of this study include a large cohort size, a prospectively maintained database, 
the use of a well-characterized comorbidity tool that has been previous validated in cancer 
patients and a long median follow-up period. The ACE-27 score also accounts for morbidity 
due to obesity, which was not a part of previously described comorbidity tools. The ACE-27 
score was determined at that time of EC diagnosis after a thorough abstraction of important 
clinical data from the medical records by registrars who completed a comorbidity education 
program. We only included patients who underwent staging surgery as this is usually the 
standard of care in the initial treatment of EC. Therefore, our results are only generalizable 
to patients able to undergo surgery. Stage information was available on all patients and was 
based on the current FIGO guidelines released in 2009. We did not include patients with 
carcinosarcomas or other sarcomas since prognosis is much worse and uterine sarcomas are 
considered a separate disease than endometrial cancer.
Limitations include the inherent biases of retrospective research and information abstracted 
from large databases. While we adjust for known confounders in our multivariable analysis, 
we cannot adjust for unmeasured and unknown confounders. Information on disease-specific 
survival would be the ideal outcome of interest in patients with prolonged survival after a 
cancer diagnosis; however, this information was not available in our database. These results 
do not apply to patients that were too ill to undergo surgery and were managed 
conservatively with hormone therapy or primary definitive radiation therapy. Finally, our 
data is based on patients treated at a single center and our findings may not be generalizable 
to the entire U.S. population of EC patients. Nonetheless, this study is the largest in the 
literature specifically evaluating the impact of medical comorbidities on survival outcomes 
of surgically treated EC patients.
Conclusions
The Adult Comorbidity Evaluation 27 score is significantly associated with mortality and 
recurrence in patients with endometrial cancer. The inclusion of comorbidity information 
during the physician-patient discussion of prognosis is essential and can help patients make 
informed decisions about adjuvant cancer treatment and management of their comorbid 
conditions.
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Figure 1. 
Flow diagram showing total patients, exclusions and distribution by Adult Comorbidity 
Evaluation 27 score.
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Figure 2. 
Kaplan-Meier survival plots for Adult Comorbidity 27 score and A) Overall survival and B) 
Recurrence-free survival.
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Figure 3. 
Kaplan-Meier overall survival plots for Adult Comorbidity 27 score stratified by cancer 
stage.
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Table 1
Organ systems and specific diseases included in ACE-27.
Cardiovascular system
 Myocardial infarct
 Angina/Coronary artery disease
 Congestive heart failure
 Arrhythmias
 Hypertension
 Venous Disease
 Peripheral arterial disease
Respiratory system
Gastrointestinal system
 Hepatic disease
 Stomach or intestinal disease
 Pancreatic disease
Renal system
 End-stage renal disease
Endocrine system
 Diabetes mellitus
Neurologic system
 Stroke
 Dementia
 Paralysis
 Neuromuscular
Psychiatric system
Rheumatologic system
Immunologic system
 AIDS
Malignancy
 Solid tumors
 Leukemia and myeloma
 Lymphoma
Substance Abuse
 Alcohol
 Illicit drugs
Obesity
ACE-27: Adult Comorbidity Evaluation-27
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Table 3
Multivariable analysis showing adjusted hazard ratio for survival and recurrence.
Characteristic Adjusted HR for death 95% CI Adjusted HR for recurrence 95% CI
Age
 < 50 Ref Ref
 50–69 1.63 1.12–2.37 1.72 1.21–2.45
 ≥ 70 3.59 2.41–5.35 3.19 2.19–4.65
Race
 White Ref
 Black 1.06 0.83–1.36 NS
 Other 1.22 0.39–3.82
Marital Status
 Married/Partner Ref Ref
 Divorced/Separated 1.14 0.84–1.54 1.15 0.87–1.53
 Widowed 1.48 1.19–1.85 1.56 1.26–1.92
 Single 1.41 1.08–1.84 1.38 1.07–1.77
 Unknown 3.68 1.50–9.03 3.11 1.27–7.59
Tobacco Use
 Never Ref Ref
 Current 1.61 1.20–2.17 1.32 1.00–1.75
 Former 1.39 1.08–1.78 1.35 1.07–1.71
 Unknown 1.23 0.96–1.57 1.05 0.83–1.34
Histology
 Endometrioid Ref Ref
 Serous 1.51 1.15–1.97 1.37 1.06–1.77
 Clear cell 1.12 0.74–1.71 1.23 0.83–1.83
Grade
 1 Ref Ref
 2 1.32 1.02–1.70 1.48 1.17–1.87
 3 2.35 1.81–3.06 2.43 1.89–3.11
Stage
 1 Ref Ref
 2 2.00 1.29–3.01 1.65 1.09–2.49
 3 4.26 3.22–5.62 3.79 2.91–4.93
 4 12.56 8.93–17.66 11.72 8.46–16.23
ACE-27 score
 None Ref Ref
 Mild 1.15 0.90–1.48 1.19 0.94–1.50
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Characteristic Adjusted HR for death 95% CI Adjusted HR for recurrence 95% CI
 Moderate 1.52 1.16–2.00 1.38 1.07–1.78
 Severe 2.35 1.73–3.21 2.05 1.53–2.75
Adjuvant therapy
 None Ref Ref
 Radiation 0.88 0.65–1.19 0.85 0.64–1.13
 Chemotherapy 0.60 0.43–0.83 0.69 0.50–0.95
 Chemo-radiation 0.44 0.33–0.68 0.60 0.44–0.83
HR: hazard ratio; CI: confidence intervals; ACE-27: Adult Comorbidity Evaluation-27.
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